IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
TREMFYA® is administered by subcutaneous injection. The recommended dose is 100 mg at Week 0, Week 4, and every 8 weeks thereafter. TREMFYA® may be administered alone or in combination with a conventional DMARD.1
TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.
In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (eg, methotrexate).
TREMFYA® is the first and only anti–IL-23 with a patient-controlled self-injection device.
- Can be used in a physician’s office or at home after physician approval and proper training
- Soft “click” indicates when the injection is complete
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.